Cargando…

A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

Bryostatin-1 is a macrocyclic lactone whose main mechanism of action is protein kinase C modulation. We investigated its activity as a weekly 24-h infusion in recurrent ovarian carcinoma. In all, 17 patients were recruited and 11 had chemotherapy-resistant disease as defined by disease progression w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clamp, A R, Blackhall, F H, Vasey, P, Soukop, M, Coleman, R, Halbert, G, Robson, L, Jayson, G C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394305/ https://www.ncbi.nlm.nih.gov/pubmed/14520436 http://dx.doi.org/10.1038/sj.bjc.6601285

Ejemplares similares

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
por: Blackhall, F H, et al.
Publicado: (2001)

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.
por: Jayson, G. C., et al.
Publicado: (1995)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro.
por: McGown, A. T., et al.
Publicado: (1998)

Antiangiogenic drugs in ovarian cancer
por: Kumaran, G C, et al.
Publicado: (2009)

Profiling Heparan Sulfate Proteoglycans in Ovarian Carcinoma
por: Clamp, Andrew R., et al.
Publicado: (2005)

Eptacog Alfa (Activated) Is Physically and Chemically Stable over 24 Hours when Administered as Bolus Injections in an Automated Infusion Pump
por: Rexen, Per, et al.
Publicado: (2019)

Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma
por: von Delius, Stefan, et al.
Publicado: (2005)

Bryostatin analog: improving on Nature's design
por: Boger, Dale
Publicado: (2012)

A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer
por: Madhusudan, S, et al.
Publicado: (2003)

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer
por: Clamp, A R, et al.
Publicado: (2006)

Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion
por: Tamura, Tomohide, et al.
Publicado: (1994)

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer
por: Hasan, J, et al.
Publicado: (2005)

Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors
por: Thijsen, S F T, et al.
Publicado: (1999)

Munc13 Is a Molecular Target of Bryostatin 1
por: Blanco, Francisco A., et al.
Publicado: (2019)

Bryostatin-1: a promising compound for neurological disorders
por: Tian, Zhen, et al.
Publicado: (2023)

Feasibility of using the Automated Self-Administered 24-hour (ASA-24) dietary assessment tool in older adults
por: Spangler, Hillary B, et al.
Publicado: (2023)

Stroke Recovery in Rats after 24‐Hour–Delayed Intramuscular Neurotrophin‐3 Infusion
por: Duricki, Denise A., et al.
Publicado: (2018)

Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study
por: Joerger, Markus, et al.
Publicado: (2023)

Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion.
por: Foster, B. J., et al.
Publicado: (1993)

A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia
por: Schimmer, Aaron D., et al.
Publicado: (2014)

Application of the Automated Self-Administered 24-Hour (ASA24) Dietary Assessment Tool's New Carbon Footprint Dataset
por: Faust, Erika, et al.
Publicado: (2022)

The clinical potential of antiangiogenic fragments of extracellular matrix proteins
por: Clamp, A R, et al.
Publicado: (2005)

Thrombosis in ovarian cancer: a case control study
por: Metcalf, R L, et al.
Publicado: (2014)

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
por: Ribas, Antoni, et al.
Publicado: (2012)

A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer
por: Kollmannsberger, C, et al.
Publicado: (2000)

Heparan sulphate synthetic and editing enzymes in ovarian cancer
por: Backen, A C, et al.
Publicado: (2007)

Neristatin 1 Provides Critical Insight into Bryostatin 1 Structure–Function Relationships
por: Kedei, Noemi, et al.
Publicado: (2015)

A phase I study of intravenous bryostatin 1 in patients with advanced cancer.
por: Prendiville, J., et al.
Publicado: (1993)

Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply.
por: Thompson, C. H., et al.
Publicado: (1996)

Validation of a self-administered web-based 24-hour dietary recall among pregnant women
por: Savard, Claudia, et al.
Publicado: (2018)

Establishment of a murine leukaemia cell line resistant to the growth-inhibitory effect of bryostatin 1.
por: Prendiville, J., et al.
Publicado: (1994)

A phase II study of bryostatin 1 in metastatic malignant melanoma.
por: Propper, D. J., et al.
Publicado: (1998)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

First-Line Management of Advanced High-Grade Serous Ovarian Cancer
por: Mahmood, Reem D., et al.
Publicado: (2020)

Association between loop diuretic dose administered in first 24 hours of heart failure admissions and length of hospital stay
por: Elashery, Ahmad Ramy, et al.
Publicado: (2018)

Predicting Perceived Problems in Self-Administered 24-Hour Dietary Recalls: A Quantitative Think-Aloud Study Comparing Automated Self-Assisted 24-Hour Dietary Assessment Tool (ASA24(®)) and INTAKE24© in University Students
por: Mackenzie, Katlyn M., et al.
Publicado: (2022)

Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion
por: Fleming, Gini F, et al.
Publicado: (2015)

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
por: Marsden, Matthew D., et al.
Publicado: (2018)

Chronic bryostatin-1 rescues autistic and cognitive phenotypes in the fragile X mice
por: Cogram, Patricia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4i5v7h12s93sp07868b92pb58s